Production (Stage)
BriaCell Therapeutics Corp.
BCTX
$3.17
$0.010.32%
NASDAQ
| 01/31/2025 | 10/31/2024 | 07/31/2024 | 04/30/2024 | 01/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -4.82% | -7.64% | -47.75% | -9.88% | 13.44% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -27.06% | -39.40% | -25.15% | 62.58% | 119.10% |
| Operating Income | 27.06% | 39.40% | 25.15% | -62.58% | -119.10% |
| Income Before Tax | 44.08% | -197.83% | 48.37% | 134.57% | 4.61% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 44.08% | -197.83% | 48.37% | 134.57% | 4.61% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 18.07% | -36.53% | -- | -- | -- |
| Net Income | 44.30% | -196.68% | 49.80% | 135.05% | 4.94% |
| EBIT | 27.06% | 39.40% | 25.15% | -62.58% | -119.10% |
| EBITDA | 27.30% | 39.69% | 26.05% | -62.62% | -119.20% |
| EPS Basic | 78.02% | -158.00% | 55.28% | 134.03% | 7.70% |
| Normalized Basic EPS | 78.07% | -157.59% | 56.04% | 134.31% | 7.89% |
| EPS Diluted | 78.02% | 55.70% | 53.74% | 133.55% | 8.22% |
| Normalized Diluted EPS | 78.07% | -160.09% | 56.04% | 134.31% | 7.89% |
| Average Basic Shares Outstanding | 153.39% | 66.71% | 12.25% | 2.99% | 2.99% |
| Average Diluted Shares Outstanding | 153.39% | 59.76% | 12.25% | 2.99% | 2.99% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |